Akio Nakajima

Summary

Affiliation: Kanazawa Medical University
Country: Japan

Publications

  1. ncbi request reprint Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity?
    Yasufumi Masaki
    Hematology and Immunology Medicine Kanazawa Medical University, Ishikawa, Japan
    J Clin Exp Hematop 53:79-85. 2013
  2. ncbi request reprint Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters
    Yasufumi Masaki
    Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada machi, Kahoku gun, Ishikawa 920 0293, Japan
    Clin Chim Acta 371:148-51. 2006
  3. ncbi request reprint IgG4-related disease: a novel lymphoproliferative disorder discovered and established in Japan in the 21st century
    Yasufumi Masaki
    Hematology and Immunology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan
    J Clin Exp Hematop 51:13-20. 2011
  4. doi request reprint High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma
    Yasufumi Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Int J Hematol 93:720-6. 2011
  5. doi request reprint Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition
    Yasufumi Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Ishikawa, Japan
    Int J Hematol 89:600-10. 2009
  6. doi request reprint Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders
    Y Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Kahoku gun, Ishikawa, 920 0293, Japan
    Ann Rheum Dis 68:1310-5. 2009
  7. doi request reprint IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights
    Yasufumi Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, Kahoku gun, Ishikawa, Japan
    J Rheumatol 37:1380-5. 2010
  8. ncbi request reprint [Primary neurolymphomatosis of the cervical nerve root]
    Miyuki Miki
    Department of Hematology and Immunology, Kanazawa Medical University
    Rinsho Ketsueki 51:564-7. 2010
  9. ncbi request reprint [Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report]
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University
    Gan To Kagaku Ryoho 39:805-7. 2012
  10. ncbi request reprint Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 31:2297-302. 2011

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity?
    Yasufumi Masaki
    Hematology and Immunology Medicine Kanazawa Medical University, Ishikawa, Japan
    J Clin Exp Hematop 53:79-85. 2013
    ..Therefore, it is necessary to conduct multicenter clinical surveys including similar cases, such as ours, to reach a consensus regarding diagnostic criteria, therapeutic strategy, and pathophysiological etiology for this syndrome...
  2. ncbi request reprint Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters
    Yasufumi Masaki
    Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada machi, Kahoku gun, Ishikawa 920 0293, Japan
    Clin Chim Acta 371:148-51. 2006
    ..We evaluated urinary pseudouridine (U-PU) as an indicator of the growth of malignant lymphoma by comparing its levels with serum concentrations of other clinical parameters in patients with various lymphomas at various stages...
  3. ncbi request reprint IgG4-related disease: a novel lymphoproliferative disorder discovered and established in Japan in the 21st century
    Yasufumi Masaki
    Hematology and Immunology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan
    J Clin Exp Hematop 51:13-20. 2011
    ..We have begun a clinical prospective study to establish a treatment strategy (Phase II prospective treatment study for IgG4-multiorgan lymphoproliferative syndrome: UMIN R000002311)...
  4. doi request reprint High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma
    Yasufumi Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Int J Hematol 93:720-6. 2011
    ..Non-hematological toxicities were tolerated well. The efficacy of this novel regimen as remission induction therapy was found to be promising in this pilot study, although the number of patients was small and follow-up short...
  5. doi request reprint Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition
    Yasufumi Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Ishikawa, Japan
    Int J Hematol 89:600-10. 2009
    ..In such cases, we can start chemotherapy based on early clinical diagnostic strategy with high sensitivity and obtain good clinical outcome...
  6. doi request reprint Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders
    Y Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Kahoku gun, Ishikawa, 920 0293, Japan
    Ann Rheum Dis 68:1310-5. 2009
    ..Mikulicz's disease (MD) has been considered as one manifestation of Sjögren's syndrome (SS). Recently, it has also been considered as an IgG(4)-related disorder...
  7. doi request reprint IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights
    Yasufumi Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, Kahoku gun, Ishikawa, Japan
    J Rheumatol 37:1380-5. 2010
    ..The Japanese IgG4 research group has begun multicenter prospective studies to improve diagnostic criteria and treatment strategies...
  8. ncbi request reprint [Primary neurolymphomatosis of the cervical nerve root]
    Miyuki Miki
    Department of Hematology and Immunology, Kanazawa Medical University
    Rinsho Ketsueki 51:564-7. 2010
    ..Primary peripheral nerve neurolymphomatosis is extremely rare. Early distinct diagnosis using (18)FDG-PET and combination chemotherapy of rituximab and high dose methotrexate may improve the outcome for such patients...
  9. ncbi request reprint [Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report]
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University
    Gan To Kagaku Ryoho 39:805-7. 2012
    ..This case report suggests that once-weekly BD therapy may reduce severe gastrointestinal adverse events without decreasing the clinical efficacy for multiple myeloma...
  10. ncbi request reprint Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 31:2297-302. 2011
    ..To establish the clinical use of bortezomib with fewer adverse events, we retrospectively analyzed the efficacy and safety of bortezomib plus dexamethasone (BD) therapy for relapsed or refractory multiple myeloma...
  11. ncbi request reprint Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 32:5437-40. 2012
    ..There are some reports that acyclovir reduces the risk of VZV reactivation. We assessed whether VZV reactivation could be reduced by using prophylactic valacyclovir at a dose of 500 mg daily...
  12. pmc Skewed production of IL-6 and TGFβ by cultured salivary gland epithelial cells from patients with Sjögren's syndrome
    Takafumi Kawanami
    Department of Hematology and Immunology, Kanazawa Medical University, Uchinada machi, Kahoku gun, Ishikawa, Japan
    PLoS ONE 7:e45689. 2012
    ..To determine the cytokine production profile of cultured salivary gland epithelial (SGE) cells obtained from patients with Sjögren's syndrome (SS)...
  13. ncbi request reprint Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 31:1741-4. 2011
    ..Four months after discontinuation of deferasirox, the blood cell count normalized and the patient became transfusion-independent. Bone marrow aspiration and biopsy revealed hematological and cytogenetic CR...
  14. ncbi request reprint Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 32:1347-53. 2012
    ....
  15. ncbi request reprint Cisplatin augments FAS-mediated apoptosis through lipid rafts
    Cheng Ri Huang
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada machi, Kahoku gun, Ishikawa 920 0293, Japan
    Anticancer Res 30:2065-71. 2010
    ..In addition, we demonstrated that membrane SM played an important role in cisplatin/CH11-induced apoptosis through the classical caspase-dependent pathway, mainly by enhancing the formation of FAS-associated signaling complexes...
  16. ncbi request reprint Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 30:3791-4. 2010
    ..The time to disease progression from the first course of BD therapy and the treatment-free interval were 400 days and 134 days, respectively...
  17. doi request reprint Deficient Leptin Signaling Ameliorates Systemic Lupus Erythematosus Lesions in MRL/Mp-Faslpr Mice
    Yoshimasa Fujita
    Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Kahoku gun, Ishikawa 920 0293, Japan
    J Immunol 192:979-84. 2014
    ..Leptin suppressed regulatory T cells and enhanced Th17 cells in vitro. In conclusion, blockade of leptin signaling may be of therapeutic benefit in patients with SLE and other autoimmune diseases. ..
  18. doi request reprint CD4+ T-cell dysfunctions through the impaired lipid rafts ameliorate concanavalin A-induced hepatitis in sphingomyelin synthase 1-knockout mice
    Lingli Dong
    Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Ishikawa 920 0293, Japan
    Int Immunol 24:327-37. 2012
    ....
  19. ncbi request reprint Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis
    Yan Cao
    Department of Hematology and Immunology, Kanazawa Medical University, Kahoku gun, Ishikawa, Japan
    Anticancer Res 30:3911-7. 2010
    ..Our data suggest that combination of SN38 and CH11 enhanced apoptosis through down-regulation of p21 phosphorylation. In conclusion, inhibition of p21 could be a new adjuvant approach in cancer therapy...
  20. pmc Cutoff Values of Serum IgG4 and Histopathological IgG4+ Plasma Cells for Diagnosis of Patients with IgG4-Related Disease
    Yasufumi Masaki
    Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Kahoku gun, Ishikawa 920 0293, Japan
    Int J Rheumatol 2012:580814. 2012
    ..Conclusion. Although a recent unanimous consensus of all relevant researchers in Japan recently established the diagnostic criteria for IgG4-related disease, findings such as ours indicate that further discussion is needed...